Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
Top Cited Papers
- 21 February 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 158 (4), 808-817
- https://doi.org/10.1111/j.1365-2133.2008.08487.x
Abstract
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studies have investigated new therapies in this setting. Objectives To assess the efficacy and safety of oral alitretinoin (9‐cis retinoic acid) taken at 10 mg or 30 mg once daily for up to 24 weeks, compared with placebo control, in the treatment of severe CHE refractory to topical corticosteroids. Methods A randomized, double‐blind, placebo‐controlled, prospective, multicentre trial was conducted in 111 dermatology outpatient clinics in Europe and Canada. A total of 1032 patients with severe refractory CHE were randomized in a 1 : 2 : 2 ratio to placebo, or 10 mg or 30 mg of oral alitretinoin once daily for up to 24 weeks. Safety was assessed for all patients during a follow‐up period of 4 weeks, and responders were observed for relapse for 24 weeks after the end of therapy. The primary efficacy parameter was Physician Global Assessment of overall CHE severity, with response defined as clear or almost clear hands. Results Responses, defined as clear or almost clear hands, were achieved in up to 48% of patients treated with alitretinoin, compared with 17% for placebo (P < 0·001), with up to 75% median reduction in disease signs and symptoms. Treatment was well tolerated, with dose‐dependent adverse effects comprising headache, mucocutaneous events, hyperlipidaemia, and decreased free thyroxine and thyroid‐stimulating hormone. The median time to relapse, defined as recurrence of 75% of initial signs and symptoms, was 5·5–6·2 months in the absence of anti‐eczema medication. Conclusions Alitretinoin given at well‐tolerated doses induced clearing of CHE in a substantial proportion of patients with severe disease refractory to standard therapy.This publication has 18 references indexed in Scilit:
- Management of chronic hand eczemaContact Dermatitis, 2007
- Quality of life and depression in a population of occupational hand eczema patientsContact Dermatitis, 2006
- Occupational skin disease in Sweden – a 12‐year follow‐upContact Dermatitis, 2005
- Construction and validation of a photographic guide for assessing severity of chronic hand dermatitisBritish Journal of Dermatology, 2005
- The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliabilityBritish Journal of Dermatology, 2005
- Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczemaBritish Journal of Dermatology, 2005
- Contact dermatitis and quality of life: a structured review of the literatureBritish Journal of Dermatology, 2003
- Hand Eczema in Swedish Adults – Changes in Prevalence between 1983 and 1996Journal of Investigative Dermatology, 2002
- The prognosis of contact dermatitisJournal of the American Academy of Dermatology, 1990
- Prevalence of eczema and other dermatoses of the hands and arms in the Netherlands. Association with age and occupationClinical and Experimental Dermatology, 1983